EP1 antagonists and genetic deletion of EP1 protect against BBB disruption following experimental ischemic stroke in rats and mice [43], and the activation of EP2 or EP4 induces vasodilation and hyperpermeability in modified Miles assays in mice [44]. The gene discussed is PTGER4; the disease is ischemic stroke.